Publications by authors named "C J Enloe"
Background: Molluscum contagiosum (MC) is a contagious viral skin infection. Berdazimer gel, 10.3% (SB206 12%) is approved in the United States as the first topical, at-home MC prescription medication.
View Article and Find Full Text PDFArticle Synopsis
- The study examined the effectiveness and safety of berdazimer gel, a topical antiviral treatment, in controlling molluscum contagiosum (MC) infections in patients with and without atopic dermatitis (AD).
- It involved a combined analysis of three Phase 3 clinical trials, where patients applied berdazimer or a placebo daily for 12 weeks, measuring the complete clearance of lesions as the primary outcome.
- Results indicated higher clearance rates for berdazimer compared to the placebo in both subgroups, though some application-site adverse effects were noted, particularly in patients with concurrent AD.
Article Synopsis
- An out-of-office treatment for molluscum contagiosum is needed, and this study evaluates the effectiveness and safety of berdazimer gel, 10.3%, compared to a placebo vehicle over 12 weeks.
- A total of 1,598 patients participated, with berdazimer showing a significantly higher complete clearance rate (30.0%) compared to the vehicle (19.8%), and it was effective across various subgroups.
- While berdazimer demonstrated positive outcomes, it also caused mild to moderate local skin reactions, like pain and redness, and the study's limitations included a focus only on US patients and no follow-up beyond 12 weeks.
Article Synopsis
- Berdazimer gel (10.3%) is a new topical treatment designed for molluscum contagiosum (MC), a common skin infection, and was tested for safety and effectiveness in a 12-week study.
- The trial involved 34 patients aged 2 to 12 years, most having around 50 MC lesions, and found that the gel had minimal systemic absorption with only mild adverse effects reported.
- Overall, the gel was considered well-tolerated, showing promising results without significant complications or high absorption rates.